Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Shuman; Robert T.
Address:
Greenwood, IN
No. of patents:
29
Patents:












Patent Number Title Of Patent Date Issued
RE37971 Selective acylation of epsilon-amino groups January 28, 2003
The present invention relates to the acylation of proteins. More particularly, the invention relates to a one-step process for selectively acylating the free .epsilon.-amino group of insulin, insulin analog, or proinsulin in the presence of a free .alpha.-amino group.
5726159 Antithrombotic agents March 10, 1998
This invention relates to thrombin inhibiting compounds having the Formula Iwhere X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and th
5646242 Selective acylation of epsilon-amino groups July 8, 1997
The present invention relates to the acylation of proteins. More particularly, the invention relates to a one-step process for selectively acylating the free .epsilon.-amino group of insulin, insulin analog, or proinsulin in the presence of a free .alpha.-amino group.
5602101 Antithrombotic agents February 11, 1997
This invention relates to L-Arginine aldehyde derivatives, pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents.
5578574 Antithrombotic agents November 26, 1996
This invention relates to L-arginine aldehyde derivatives, having the formula I ##STR1## where X and Y have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibi
5488037 Antithrombotic agents January 30, 1996
This invention relates to L-Arginine aldehyde derivatives, pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents.
5484772 Antithrombotic agents January 16, 1996
This invention relates to L-arginine aldehyde derivatives, pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents.
5455229 Method for minimizing and containing ischemic and reperfusion injury October 3, 1995
The present invention is a method for minimizing and containing injury caused when tissue is subject to ischemia and reperfusion. The method comprises administering certain derivatized tripeptide arginal compounds concurent with, or immediately after, reestablishing blood flow to the
5439888 Antithrombotic agents August 8, 1995
This invention relates to L-Arginine aldehyde derivatives, pharmaceutical formulations containing those compound and methods of their use as thrombin inhibitors.
5436229 Bisulfite adducts of arginine aldehydes July 25, 1995
This invention relates to bisulfite adducts of L-Arginine aldehyde derivatives, pharmaceutical formulations containing those adducts and methods of their use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents.
5430023 Tripeptide antithrombotic agents July 4, 1995
Thrombin inhibitors represented by the formula ##STR1## as provided wherein A(C.dbd.O)-- is, inter alia, phenylglycyl, cyclohexylglycyl, cyclohexenylglycyl, thienylglycyl or naphthylglycyl, wherein the .alpha.-amino group is preferably substituted by alkyl e.g. methyl or an alkox
5416093 Antithrombotic agents May 16, 1995
Thrombin inhibitors represented by the formula ##STR1## as provided wherein A is e.g. phenylglycyl, and phenylalanyl, .alpha.-methylphenylalanine and .alpha.-methylphenylglycine wherein the amino group is preferably substituted with lower alkyl alkanoyl or lower alkoxycarbonyl, o
5252566 Antithrombotic agents October 12, 1993
Thrombin inhibitors represented by the formula ##STR1## as provided wherein A is e.g. phenylglycyl, and phenylalanyl, .alpha.-methylphenylalanine and .alpha.-methylphenylglycine wherein the amino group is preferably substituted with lower alkyl alkanoyl or lower alkoxycarbonyl, o
5250660 Peptide purification process October 5, 1993
Tripeptides, D-Phe-L-Pro-L-Arg-H, D-Phg-L-Pro-L-Arg-H and related compounds are purified in a process comprising 1) HPLC chromatography over an alkylsilane resin and elution with a gradient comprising an organic phase of between about 2% and about 40% of acetonitrile in an aqueous acidic
4510082 Pharmacologically active peptides April 9, 1985
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in whichR is hydrogen, methyl, ethyl, cyclopropylmethyl, or allyl;A is a residue of a D-amino acid selected from the goup consisting of Ala, Abu, Nva, Val, Nle, Leu, Ile, Gly(Al),
4473497 Pharmacologically active peptides September 25, 1984
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in whichR is hydrogen, methyl, ethyl, cyclopropylmethyl, or allyl;A is a residue of a D-amino acid selected from the group consisting of Ala, Abu, Nva, Val, Nle, Leu, Ile, Gly(Al)
4448717 Pharmacologically active peptides May 15, 1984
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in whichR is hydrogen, methyl, ethyl, cyclopropylmethyl, or allyl;A is a residue of a D-amino acid selected from the group consisting of Ala, Abu, Nva, Val, Nle, Leu, Ile, Gly(Al)
4351763 Pharmacologically active peptides September 28, 1982
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in whichL and D define the chirality;R.sub.1 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.2 is C.sub.1 -C.sub.4 primary or secondary alkyl, allyl, cyclopropylmethyl, C.sub.
4333873 Pharmacologically active peptides June 8, 1982
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D define the chirality;R.sub.1 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.2 is C.sub.1 -C.sub.4 primary or secondary alkyl, allyl, cyclopropylmethyl, C.sub
4331593 Analgesic compounds May 25, 1982
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D, when applicable, define the chirality;R.sub.1 and R.sub.2 independently are hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.3 is C.sub.1 -C.sub.4 primary or sec
4322342 Analgesic compounds March 30, 1982
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which:L and D, when applicable, define the chirality;R.sub.1 is hydrogen, C.sub.1 -C.sub.3 primary alkyl, or allyl;R.sub.2 is hydrogen or C.sub.1 -C.sub.3 primary alkyl, subject to
4322340 Pharmacologically active peptides March 30, 1982
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in whichR is hydrogen, methyl, ethyl, cyclopropylmethyl, or allyl;A is a residue of a D-amino acid selected from the group consisting of Ala, Abu, Nva, Val, Nle, Leu, Ile, Gly(Al)
4322339 Pharmacologically active peptides March 30, 1982
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in whichR is hydrogen, methyl, or ethyl;A is the residue of a D-amino acid selected from the group consisting of Ala, Abu, Nva, Val, Nle, Leu, Ile, Gly(Al), Gly(Cp), Met, Cys(Me),
4283330 Pharmacologically active peptides August 11, 1981
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D define the chirality;R.sub.1 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.2 is C.sub.1 -C.sub.4 primary or secondary alkyl, allyl, cyclopropylmethyl, C.sub
4283329 Pharmacologically active peptides August 11, 1981
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D define the chirality;R.sub.1 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.2 is C.sub.1 -C.sub.4 primary or secondary alkyl, allyl, cyclopropylmethyl, C.sub
4265808 Pharmacologically active peptides May 5, 1981
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D define the chirality;R.sub.1 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.2 is C.sub.1 -C.sub.4 primary or secondary alkyl, allyl, cyclopropylmethyl, C.sub
4264491 Analgesic compounds April 28, 1981
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D, when applicable, define the chirality;R.sub.1 and R.sub.2 independently are hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.3 is C.sub.1 -C.sub.4 primary or sec
4259234 Analgesic compounds March 31, 1981
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D, when applicable, define the chirality;R.sub.1 is hydrogen, C.sub.1 -C.sub.3 primary alkyl, or allyl;R.sub.2 is hydrogen or C.sub.1 -C.sub.3 primary alkyl, subject to
4199499 Pharmacologically active peptides April 22, 1980
Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D define the chirality;R.sub.1 and R.sub.2 independently are hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.3 is C.sub.1 -C.sub.4 primary or secondary alkyl, C.su










 
 
  Recently Added Patents
Specification of latency in programmable device configuration
Automatic adjustment of devices in a home entertainment system
Center spreader adapter tool for toilet paper rolls and paper towel rolls that do not have inner cardboard tubes
Photoelectric conversion device
System and method for secure power systems infrastructure communications
Off-loading of processing from a processor blade to storage blades based on processing activity, availability of cache, and other status indicators
Reusing data in user run book automation
  Randomly Featured Patents
Expression vector
Methods and apparatuses for detecting medical device acceleration, temperature, and humidity conditions
Low-shrinkage polyester film and preparation thereof
Metal-detection gateway control and display unit
Signal transmitting apparatus
Bypass air injection method and apparatus for gas turbines
Remote control of cymbal apparatus
Mount for a navigation system
Infant teething toy
Thin film transistor having plural semiconductive oxides, thin film transistor array panel and display device including the same, and manufacturing method of thin film transistor